MoneyWorks4Me

Marksans Pharma informs about disclosure

02 Apr 2019 Evaluate

In compliance with the SEBI (Prohibition of insider Trading) (Amendment) Regulations, 2018, Marksans Pharma has informed that the Board of directors of the Company has adopted revised Code of Practices and Procedures For Fair Disclosure of Unpublished Price Sensitive Information effective from April 1, 2019. The said revised code is attached herewith and is also available on the Company's website at www.marksanspharma.com.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..